The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

ZURICH (Reuters) -Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its ...

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of ...

Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from the tariff wars, Maggie Fick of ...